
浏览全部资源
扫码关注微信
贵州医科大学 贵州省药物制剂重点实验室/省部共建药用植物功效与利用国家重点实验室,民族药与中药开发应用教育部工程研究中心,药学院,贵阳 550004
朱晓青,在读硕士,从事中药药效物质基础研究,E-mail:1358402320@ qq.com
王永林,教授,从事中药药效物质基础研究,E-mail:gywyl@gmc.edu.cn
收稿日期:2020-10-05,
网络出版日期:2021-01-26,
纸质出版日期:2021-04-20
移动端阅览
朱晓青,陆苑,刘亭等.艾迪注射液对DEN诱导型肝癌大鼠体内细胞色素P450酶表达的影响[J].中国实验方剂学杂志,2021,27(08):43-49.
ZHU Xiao-qing,LU Yuan,LIU Ting,et al.Effect of Aidi Injection on Expression of Cytochrome P450 Enzyme in DEN-induced Hepatocellular Carcinoma Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):43-49.
朱晓青,陆苑,刘亭等.艾迪注射液对DEN诱导型肝癌大鼠体内细胞色素P450酶表达的影响[J].中国实验方剂学杂志,2021,27(08):43-49. DOI: 10.13422/j.cnki.syfjx.20210721.
ZHU Xiao-qing,LU Yuan,LIU Ting,et al.Effect of Aidi Injection on Expression of Cytochrome P450 Enzyme in DEN-induced Hepatocellular Carcinoma Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(08):43-49. DOI: 10.13422/j.cnki.syfjx.20210721.
目的
2
观察艾迪注射液(AD)对二乙基亚硝胺(DEN)化学诱导的原发性肝癌(HCC)大鼠体内细胞色素P450(CYP450)4种亚型酶CYP1A2,CYP2E1,CYP3A2,CYP2C11 mRNA和蛋白表达的影响。
方法
2
健康SD雄大鼠随机选取3只作为空白组,余下大鼠采用DEN间断性诱导原发性肝癌大鼠模型,模型成功后随机将大鼠分为模型组,AD组,每组3只。正常组与模型组腹腔注射10 mL·kg
-1
生理盐水,AD组腹腔注射10 mL·kg
-1
AD,1 次/d,共干预14 d。采用实时荧光定量聚合酶链式反应(Real-time PCR)和蛋白免疫印迹法(Western blot)分别检测CYP1A2,CYP2E1,CYP3A2,CYP2C11 mRNA和蛋白的表达。
结果
2
Real-time PCR结果表明,给药14 d,与正常组比较,模型组大鼠癌旁组织(PCT)和癌灶组织(CT)CYP1A2,CYP2E1,CYP3A2,CYP2C11 mRNA表达均明显下调(
P<
0.05,
P<
0.01);与模型组比较,AD组PCT中4种亚型酶mRNA表达明显下调(
P
<
0.05,
P<
0.01),CT中4种亚型酶mRNA表达明显上调(
P
<
0.05)。Western blot结果表明,与正常组比较,模型组CT中CYP1A2,CYP2E1,CYP3A2,CYP2C11蛋白表达均显著下调(
P
<
0.01),PCT中CYP3A2,CYP2C11蛋白表达显著下调(
P
<
0.01);与模型组比较,AD组CT,PCT中CYP1A2,CYP2E1,CYP3A2,CYP2C11蛋白表达有下调趋势,差异无统计学意义。
结论
2
AD可下调大鼠肝组织中CYP1A2,CYP2E1,CYP3A2,CYP2C11 mRNA和蛋白的表达。临床使用AD时,应注意可能因CYP450酶抑制引起的药物相互作用。
Objective
2
To study the effect of Aidi injection (AD) on the expression of cytochrome P450 isoenzyme 1A2,2E1,3A2,2C11(CYP1A2,2E1,3A2,2C11)mRNA and protein in rats with N-nitrosodiethylamine (DEN) chemically induced primary hepatocellular carcinoma(HCC).
Method
2
Three healthy SD male rats were randomly selected as the blank group, and the remaining rats were treated with DEN intermittently induced primary hepatocellular carcinoma rat model. After success of the model, the rats were randomly divided into model group and AD group, with 3 rats in each group. The rats in the blank group and model group were intraperitoneally injected with 10 mL·kg
-1
saline, while those in the AD group were intraperitoneally injected with 10 mL·kg
-1
AD once a day, a total of 14 d intervention. Real-time quantitative polymerase chain reaction(Real-time PCR) and Western blot were used to detect the mRNA and protein expressions of CYP1A2, CYP2E1, CYP3A2 and CYP2C11, respectively.
Result
2
Real-time PCR results showed that after 14 days of drug administration, compared with the blank group, the mRNA expressions of CYP1A2, CYP2E1, CYP3A2 and CYP2C11 were all down-regulated in para-cancerous tissue (PCT) and cancerous tissue (CT) in model group, and there were significant differences (
P
<
0.05,
P<
0.01). Compared with the model group, the mRNA expressions of the four subtype enzyme were significantly down-regulated in PCT in the AD group(
P
<
0.05,
P<
0.01), while the mRNA expressions of the four subtype enzyme were significantly up-regulated in CT (
P
<
0.05), and the expression was down-regulated overall. Western blot results showed that compared with the blank group, the protein expressions of CYP1A2, CYP2E1, CYP3A2 and CYP2C11 in CT of the model group were significantly down-regulated (
P
<
0.01), and the protein expressions of CYP3A2 and CYP2C11 were significantly down-regulated in PCT (
P
<
0.01). Compared with the model group, the protein expressions of CYP1A2, CYP2E1, CYP3A2 and CYP2C11 in CT and PCT were down-regulated in the AD group, but the differences were not statistically significant.
Conclusion
2
AD can down-regulate the mRNA and protein expressions of CYP1A2, CYP2E1, CYP3A2 and CYP2C11 in rat liver tissues. In clinical use of AD, attention should be paid to drug interactions that may be caused by CYP450 enzyme inhibition.
王国栋 , 米淑玲 . 复方斑蝥注射液在中西医结合治疗恶性肿瘤中的临床研究与应用进展 [J]. 医学综述 , 2011 , 17 ( 5 ): 779 - 781 .
何红 . 艾迪注射液联合化疗治疗老年非小细胞肺癌效果观察 [J]. 临床合理用药杂志 , 2020 , 13 ( 13 ): 51 - 53 .
韩瑜 . 艾迪注射液联合XELOX化疗治疗晚期原发性肝癌的临床效果 [J]. 河南医学研究 , 2020 , 29 ( 8 ): 1439 - 1440 .
肖吝生 . 艾迪注射液联合化疗治疗中、晚期癌症患者的临床分析 [J]. 药品评价 , 2019 , 16 ( 20 ): 70 - 71 .
WANG X L , JIN W M , FANG B M , et al . Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: a Meta-analysis based on randomized controlled trials [J]. J Cancer Res Ther , 2016 , 12 ( 5 ): 11 - 14 .
祝永福 , 张东伟 , 宇明慧 , 等 . 艾迪注射液联合化疗对晚期胃癌患者临床疗效及癌因性疲乏、生活质量的影响 [J]. 湖北中医药大学学报 , 2019 , 21 ( 4 ): 29 - 33 .
邱楠 , 陈小凤 , 艾长江 , 等 . 艾迪注射液联合化疗治疗卵巢癌的疗效及安全性Meta分析 [J]. 世界中西医结合杂志 , 2019 , 14 ( 4 ): 467 - 472,480 .
潘莹 , 邓颖 , 毕惠嫦 , 等 . 隐丹参酮对大鼠肝微粒体CYP酶的影响 [J]. 中药新药与临床药理 , 2009 , 20 ( 4 ): 331 - 334 .
JIN S E , SEO C S , SHIN H K , et al . Traditional herbal formulas to as treatments for musculoskeletal disorders: their inhibitory effects on the activities of human microsomal cytochrome P450s and UDP-glucuronosyltransferases [J]. Pharmacogn Mag , 2016 , 12 ( 48 ): 241 - 252 .
SHEN Z , WANG Y , GUO W , et al . Potential herb-drug interaction of shexiang baoxin pill in vitro based on drugmetabolism/transporter [J]. Am J Transl Res , 2016 , 8 ( 12 ): 5545 - 5556 .
JIN S E , HA H , SEO C S , et al . Expression of cytochrome P450s in the liver of rats administered with socheongryong-tang, a traditional herbal formula [J]. Pharmacogn Mag , 2016 , 12 ( 47 ): 211 - 218 .
PANDIT S , KANJILAL S , AWASTHI A , et al . Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay [J]. J Ethnopharmacol , 2017 , 197 : 165 - 172
YANG F C , ZHENG S S , IANG T A . The establishment of primary liver cancer model in rats improved method [J]. Natl Med J Chin , 2004 , 84 ( 23 ): 2018 - 2019 .
陆苑 , 潘洁 , 杨淑婷 , 等 . 艾迪注射液对肝癌大鼠谷胱甘肽- S -转移酶的影响 [J]. 中国药理学通报 , 2018 , 34 ( 8 ): 1170 - 1174 .
《原发性肝癌诊疗规范》编写专家委员会 . 原发性肝癌诊疗规范(2019年版) [J], 中国临床医学 , 2020 , 27 ( 1 ): 140 - 160 .
CHIANG M H , CHANG L W , WANG J W , et al . Herb-drug pharmacokinetic interaction of a traditional chinese medicine jia-wei-xiao-yao-san with 5-fluorouracil in the blood and brain of rat using microdialysis [J]. Evid-Based Compl Alt , 2015 , doi: org/10.1155/2015/729679 http://dx.doi.org/org/10.1155/2015/729679 .
韦武 , 郭红星 . 大鼠肝癌模型建立的研究进展 [J]. 中国实验动物学报 , 2019 , 27 ( 1 ): 119 - 123 .
李果 , 朱柱 , 戴小明 , 等 . 肝癌动物模型建立的研究进展 [J]. 医学综述 , 2018 , 24 ( 2 ): 285 - 289 .
张嘉宁 , 顾为望 , 许乙凯 , 等 . 大鼠肝癌模型的建立及影像学表现 [J]. 中国实验动物学杂志 , 1999 , 9 ( 2 ): 37 - 40 .
HOHMANN N , HAEFELI W E , MIKUS G . CYP3A activity: towards dose adaptation to the individual [J]. Expert Opin Drug Met , 2016 , 12 ( 5 ): 479 - 497 .
林琴 , 贾金雪 , 王涛 , 等 . 抑制NF- κ B的活化对免疫性肝损伤大鼠CYP1A2的影响 [J]. 中国药理学通报 , 2018 , 34 ( 11 ): 1605 - 1609 .
李智 , 王果 , 周宏灏 . CYP2C9基因多态性及其功能意义研究进展 [J]. 中国临床药理学与治疗学 , 2008 ( 6 ): 601 - 609 .
赵阳阳 , 许智慧 , 刘妍 , 等 . 细胞色素P450基因多态性与药物代谢研究进展 [J]. 临床药物治疗杂志 , 2017 , 15 ( 4 ): 1 - 6 .
PORUBSKY P R , MENEELY K M , SCOTT E E . Structures of human cytochrome P-4502E1.Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates [J]. J Biol Chem , 2008 , 283 ( 48 ) : 33698 - 33707 .
VKOCAREK T A , ZANGAR R C , NOVAK R F . Post-transcriptional regula-tion of rat CYP2E1 expression: role of CYP2E1 mRNA untrans-lated regions in control of translational efficiency and message sta-bility [J]. Arch Biochem Biophys , 2000 , 376 ( 1 ) : 180 - 190 .
HAN Y L , LI D , REN B , et al . Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs [J]. J Ethnopharmacol , 2012 , 139 ( 1 ): 104 - 109 .
汤红霞 , 王梦影 , 庹婧 , 等 . 艾迪注射液联合VAD化疗方案治疗多发性骨髓瘤患者的效果 [J]. 中国医药导报 , 2018 , 15 ( 25 ): 67 - 70,74 .
施子夏 , 张劲 , 张兵兵 , 等 . 艾迪注射液联合TP方案治疗非小细胞肺癌的临床观察 [J]. 中国药房 , 2016 , 27 ( 23 ): 3234 - 3237 .
陆国权 , 周晓红 , 陈红 , 等 . 艾迪注射液辅助利妥昔单抗联合CHOP化疗方案治疗弥漫性大B细胞淋巴瘤 [J]. 中国实验血液学杂志 , 2016 , 24 ( 3 ): 733 - 737 .
DENG S , KRUGER A , KLESCHYOV A L . Gp91phox-containing NAD (P) H oxidase increases superoxide formation by doxorubicin and NADPH [J]. Free Radical Bio Med , 2017 , 42 ( 4 ): 466 - 473 .
王向文 . CYP3A4基因单核苷酸多态性同儿童ALL大剂量甲氨蝶呤治疗不良反应的相关性研究 [D]. 重庆 : 重庆医科大学 , 2016 .
王淑梅 , 孙路路 , 曾蔚欣 , 等 . 细胞色素P450 2E1基因多态性与急性淋巴细胞白血病易感性及其与甲氨蝶呤血清浓度关系探讨 [J]. 中国临床药理学杂志 , 2014 , 30 ( 9 ): 773 - 775,779 .
杨建伟 , 苏颖 , 陈增 , 等 . CYP3A4基因多态性与晚期胃癌患者接受紫杉醇/奥沙利铂多线化疗、化疗周期数及不良反应的相关性 [J]. 临床与病理杂志 , 2014 , 34 ( 1 ): 22 - 28 .
ZHOU D , LU Y , STEINER M S , et al . Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect .[J]. Antimicrob Agents Chemother , 2000 , 44 : 2659 - 2663 .
耿祥飞 , 张广州 , 任娟 , 等 . 紫杉醇对食蟹猴和人CYP1A2、CYP3A4及CYP2A6酶代谢的影响 [J]. 中国比较医学杂志 , 2010 , 20 ( 9 ): 30 - 33 .
0
浏览量
16
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621